GlassScriptPhysician profile
John J Digioia
NPI 1154359255
$1,921.43
in general payments reported to CMS, 2019-2025
25 companies · $876 in 2025
The $876 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $671 · 2024: $374 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.84 | 2024-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $193.15 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $184.07 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Intra-Sana Laboratories | $181.85 | 2024-2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Lilly USA, LLC | $177.24 | 2023-2025 | Mounjaro, Jardiance, Emgality |
| Abbott Laboratories | $111.32 | 2024-2025 | Freestyle Libre |
| Medtronic, INC. | $109.69 | 2023 | Interstim |
| Mannkind Corporation | $105.32 | 2023 | Afrezza |
| Abbvie INC. | $84.01 | 2023 | Vraylar, Dalvance |
| Viiv Healthcare Company | $69.54 | 2025 | Apretude |
| Scilex Pharmaceuticals INC. | $67.14 | 2024-2025 | |
| Philips North America LLC | $60.52 | 2024-2025 | Mcot, (Ck7) Extended Holter |
| Inspire Medical Systems, INC. | $50.68 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $47.81 | 2023 | Arexvy, Trelegy Ellipta |
| Biotronik Nro, INC. | $47.59 | 2024-2025 | Prospera |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $38.78 | 2023 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.71 | 2023 | |
| Currax Pharmaceuticals LLC | $29.05 | 2025 | Contrave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.54 | 2023 | Stiolto Respimat, Jardiance |
| Xeris Pharmaceuticals, INC. | $19.53 | 2024 | Gvoke Hypopen |
| Bausch Health US, LLC | $18.68 | 2025 | Aplenzin |
| Pfizer INC. | $17.19 | 2025 | |
| Alkermes, INC. | $17.01 | 2025 | Vivitrol |
| Astellas Pharma US INC | $16.91 | 2025 | Veozah |
| Evofem Biosciences, INC. | $15.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Digioia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.